Therefore, assessing the JAK2 V617F mutant allele burden (% JAK2 V617F) and its correlation with phenotypic markers is critical for optimizing diagnostic criteria and monitoring disease progression in MPN patients. Here, JAK2 is linked to myeloproliferative neoplasm.